Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
This study has been completed.
Study NCT00003204 Information provided by National Cancer Institute (NCI)
First Received on May 2, 2000. Last Updated on February 26, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Stage IV Small Lymphocytic Lymphoma
Additional conditions recognized in this trial
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma
Lymphoma, Follicular
Lymphoma, Non-Hodgkin
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Leukemia
Leukemia, B-Cell
Leukemia, Lymphoid
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
cyclophosphamide
fludarabine phosphate
vincristine sulfate
prednisone
rituximab
laboratory biomarker analysis
Additional drug interventions recognized in this trial
Antibodies
Antibodies, Monoclonal
Fludarabine
Fludarabine monophosphate
Immunoglobulins
Vidarabine
Vincristine
More general drug interventions related to this trial
Alkylating Agents
Anti-Infective Agents
Anti-Inflammatory Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Antineoplastic Agents, Phytogenic
Antirheumatic Agents
Antiviral Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
